文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

比较分析确定改善大鼠失血性休克后生存与器官损伤的最佳组蛋白去乙酰化酶抑制剂及给药途径

A COMPARATIVE ANALYSIS TO DETERMINE THE OPTIMUM HISTONE DEACETYLASE INHIBITORS AND ADMINISTRATION ROUTE FOR IMPROVING SURVIVAL AND ORGAN INJURY IN RATS AFTER HEMORRHAGIC SHOCK.
PubMed 文献 · Shock · 2023-05-05
一句话结论大鼠失血性休克模型中,静脉给予组蛋白去乙酰化酶抑制剂(HDACI)效果优于腹腔给药,非选择性与I类和IIb亚型选择性HDACI效果相似。

该研究在大鼠失血性休克模型(平均动脉压维持于30-40 mm Hg 20分钟)中,实验I静脉注射7种HDACI(每组n=8)比较生存与器官损伤,实验II腹腔注射曲古抑菌素A(TSA)比较给药途径。实验I中,载体组75%大鼠在治疗后≤5小时内死亡,而LMK-235和sirtinol组仅25%死亡,MS-275、tubastatin A和TSA组生存显著延长。实验II中静脉TSA生存长于腹腔TSA,但腹腔TSA组心脏IL-6水平显著低于静脉TSA组。结论认为静脉效果优于腹腔,非选择性与I类和IIb亚型选择性HDACI效果相似。

要点

  • 实验I中载体组75%大鼠在治疗后≤5小时内死亡,而LMK-235和sirtinol组仅25%大鼠死亡。
  • MS-275、tubastatin A和TSA组大鼠生存较载体组显著延长。
  • MS-275、LMK-235、tubastatin A和TSA显著降低组织病理学评分、凋亡细胞数和炎症细胞因子水平。
  • 实验II中静脉TSA治疗后的生存时间长于腹腔TSA治疗。
  • 实验II中腹腔TSA组心脏IL-6水平显著低于静脉TSA组。

适用人群与场景

  • 雄性Sprague-Dawley大鼠,失血性休克模型(平均动脉压维持于30-40 mm Hg 20分钟)。

处置流程与药物剂量

  • 实验I:失血性休克后静脉注射以下药物(每组n=8):无治疗、载体(VEH)、恩替诺特(MS-275)、LMK-235、tubastatin A、曲古抑菌素A(TSA)、sirtinol。
  • 实验II:失血性休克后腹腔注射TSA。
  • 实验I和II中观察大鼠3小时,随后采集血样及肝、心、肺组织。

研究设计与关键结果

  • 实验I中,载体组75%大鼠在治疗后≤5小时内死亡,而LMK-235和sirtinol组仅25%大鼠死亡。
  • 实验I中,MS-275、tubastatin A和TSA组大鼠生存较载体组显著延长。
  • 实验I中,MS-275、LMK-235、tubastatin A和TSA显著降低组织病理学评分、凋亡细胞数和炎症细胞因子水平。
  • 实验II中,静脉TSA治疗后的生存时间长于腹腔TSA治疗。
  • 实验II中,腹腔TSA组心脏IL-6水平显著低于静脉TSA组。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠失血性休克模型)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论认为,静脉给药效果优于腹腔给药,非选择性与I类和IIb亚型选择性HDACI效果相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Objective: Histone deacetylase inhibitors (HDACIs) have been reported to improve survival in rats with hemorrhagic shock (HS). However, no consensus exists on the most effective HDACIs and their administration routes. We herein aimed to determine the optimal HDACIs and administration route in rats with HS. Methods: Survival analysis: In experiment I, male Sprague-Dawley rats were subjected to HS (mean arterial pressure [MAP] was maintained at 30-40 mm Hg for 20 min), and intravenously injected with the following agents (n = 8 per group): (1) no treatment, (2) vehicle (VEH), (3) entinostat (MS-275), (4) [ N -((6-(Hydroxyamino)-6-oxohexyl)oxy)-3,5-dimethylbenzamide] (LMK-235), (5) tubastatin A, (6) trichostatin A (TSA), and (7) sirtinol. In experiment II, rats were intraperitoneally injected with TSA. Mechanism research: In experiments I and II, rats were observed for 3 h, after which blood samples and liver, heart, and lung tissues were harvested. Results: In experiment I, 75% rats in the VEH group but only 25% rats in the LMK-235 and sirtinol groups died within ≤5 h of treatment, whereas the survival of rats in the MS-275, tubastatin A, and TSA groups was significantly prolonged. MS-275, LMK-235, tubastatin A, and TSA significantly reduced histopathological scores, apoptosis cell numbers, and inflammatory cytokine levels. In experiment II, the survival was longer after i.v. TSA treatment than after i.p. TSA treatment, and the IL-6 levels in the heart were significantly lower in rat who received i.p. TSA treatment than in those who received i.v. TSA treatment. Conclusions: The i.v. effect was superior to the i.p. effect, while nonselective and isoform-specific classes I and IIb HDACIs had similar effects.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Niu K, Yang L, Song W, et al. A COMPARATIVE ANALYSIS TO DETERMINE THE OPTIMUM HISTONE DEACETYLASE INHIBITORS AND ADMINISTRATION ROUTE FOR IMPROVING SURVIVAL AND ORGAN INJURY IN RATS AFTER HEMORRHAGIC SHOCK. Shock. 2023. PMID: 37141162. doi:10.1097/SHK.0000000000002136

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。